Discover the fascinating realm of BridgeBio Pharma (BBIO -5.42%) with our knowledgeable analysts in this episode of the Motley Fool Scoreboard. Watch the video below to learn about market trends and possible investment chances!
We have just released a list of the 10 Best Performing Mid Cap Stocks to Buy Based on Analyst Recommendations. In this article, we will examine how BridgeBio Pharma, Inc. (NASDAQ:BBIO) compares to other top mid cap stocks recommended by analysts. On February 7, Simeon Hyman, a Global Investment Strategist at […]
PALO ALTO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) has announced the pricing of $500 million in 1.75% convertible senior notes that will mature in 2031. This private offering is aimed at qualified institutional buyers and follows Rule 144A of the Securities Act of 1933. Additionally, the Company has given initial buyers the option to purchase up to $75 million more in notes, with the sale expected to finalize on February 28, 2025, pending standard closing conditions.
Attruby has had a successful beginning in the United States, achieving over 1,000 unique prescriptions in under three months after receiving FDA approval. I expect to see more patients using Attruby by the end of the year than I initially thought, although the growth might slow down in the second quarter due to the launch of Alnylam's Amvuttra. Additionally, the company is making progress with its pipeline, as three important trials are expected to release results in the next year.
PALO ALTO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a biopharmaceutical company that focuses on genetic diseases. They have received approval from the European Commission to market acoramidis, branded as BEYONTTRA™, for treating wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy (ATTR-CM). This drug is an oral medication that stabilizes transthyretin (TTR) and is intended for a serious heart condition that can lead to heart failure, with Bayer handling its commercial activities in the EU.
We have just released a list of 10 Unstoppable Stocks to Invest in for 2025. In this article, we will examine how BridgeBio Pharma, Inc. (NASDAQ:BBIO) compares to other top stocks to buy in 2025. According to the latest earnings report from FactSet on January 24, 2025, the earnings season for Q4 2024 is underway.
Attruby's recent approval makes BBIO a direct rival to PFE's Vyndaqel in treating ATTR-CM. With a 42% decrease in heart failure risk and 90% TTR stabilization, Attruby may offer better results than Vyndaqel in certain situations. Additionally, BBIO is expected to receive $500 million in milestone payments for Attruby's approval, along with another $105 million from approvals in the EU and Japan.
Neil Kumar, the CEO of BridgeBio, appears on CNBC's 'Power Lunch' to talk about the company's newest drug advancements, how these drugs stack up against rivals, and other related topics.
We have just released a list of 10 companies that led the rise on Monday. In this article, we will examine how BridgeBio Pharma, Inc. (NASDAQ:BBIO) compares to these other firms that experienced significant gains. Most of these ten companies are in the healthcare sector and started Monday's trading with impressive increases due to various business updates and earnings reports.
BridgeBio Pharma (BBIO) experienced a significant rise in its stock price during the last trading session, with trading volume exceeding the usual amount. However, the recent changes in earnings estimates might not lead to additional price growth in the short term.